MetaVia Inc. (MTVA), a clinical-stage biotechnology company, Tuesday reported positive results from the 4-week multiple ascending dose (MAD) Part 2 of its Phase 1 study of DA-1726 for the treatment of obesity.
The Phase 1 study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of DA-1726 in obese, otherwise healthy subjects. In the MAD portion of the study, DA-1726 showed excellent safety and tolerability, with positive clinical activity. The cohort receiving 32 mg of DA-1726 with no titration demonstrated a maximum weight loss of 6.3 percent and a mean weight loss of 4.3 percent at day 26.
With the mean baseline of 41 inches, DA-1726 showed an average reduction in waist circumference of 1.6 inches, with a maximum reduction of 3.9 inches by day 33.
The company plans to conduct a Phase 1 Part 3 study to evaluate DA-1726 on Wegovy early drop-out patients. Novo Nordisk's Wegovy is approved by the FDA for chronic weight management in adults with obesity.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.